Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to compare the efficacy of liver transplantation (LT) and liver resection (LR) for hepatocellularcarcinoma (HCC) patients with portal vein tumor thrombus (PVTT) and to investigate risk factors affecting prognosis. Materials and Methods: A total of 94 HCC patients with PVTT type I (segmental PVTT) and PVTT type II (lobar PVTT) were involvedand divided into LR (n=47) and LT groups (n=47). Recurrence-free survival (RFS) and overall survival (OS) were comparedbefore and after inverse probability of treatment weighting (IPTW). Prognostic factors for RFS and OS were explored. Results: Two treatment groups were well-balanced using IPTW. In the entire cohort, LT provided a better prognosis than LR. Among patients with PVTT type I, RFS was better with LT (p=0.039); OS was not different significantly between LT and LR(p=0.093). In subgroup analysis of PVTT type I patients with α-fetoprotein (AFP) levels >200 ng/mL, LT elicited significantly longermedian RFS (18.0 months vs. 2.1 months, p=0.022) and relatively longer median OS time (23.6 months vs. 9.8 months, p=0.065). Among patients with PVTT type II, no significant differences in RFS and OS were found between LT and LR (p=0.115 and 0.335,respectively). Multivariate analyses showed treatment allocation (LR), tumor size (>5 cm), AFP and aspartate aminotransferase(AST) levels to be risk factors of RFS and treatment allocation (LR), AFP and AST as risk factors for OS. Conclusion: LT appeared to afford a better prognosis for HCC with PVTT type I than LR, especially in patients with AFP levels>200 ng/mL.
Abstract
Purpose: The aim of this study was to compare the efficacy of liver transplantation (LT) and liver resection (LR) for hepatocellularcarcinoma (HCC) patients with portal vein tumor thrombus (PVTT) and to investigate risk factors affecting prognosis. Materials and Methods: A total of 94 HCC patients with PVTT type I (segmental PVTT) and PVTT type II (lobar PVTT) were involvedand divided into LR (n=47) and LT groups (n=47). Recurrence-free survival (RFS) and overall survival (OS) were comparedbefore and after inverse probability of treatment weighting (IPTW). Prognostic factors for RFS and OS were explored. Results: Two treatment groups were well-balanced using IPTW. In the entire cohort, LT provided a better prognosis than LR. Among patients with PVTT type I, RFS was better with LT (p=0.039); OS was not different significantly between LT and LR(p=0.093). In subgroup analysis of PVTT type I patients with α-fetoprotein (AFP) levels >200 ng/mL, LT elicited significantly longermedian RFS (18.0 months vs. 2.1 months, p=0.022) and relatively longer median OS time (23.6 months vs. 9.8 months, p=0.065). Among patients with PVTT type II, no significant differences in RFS and OS were found between LT and LR (p=0.115 and 0.335,respectively). Multivariate analyses showed treatment allocation (LR), tumor size (>5 cm), AFP and aspartate aminotransferase(AST) levels to be risk factors of RFS and treatment allocation (LR), AFP and AST as risk factors for OS. Conclusion: LT appeared to afford a better prognosis for HCC with PVTT type I than LR, especially in patients with AFP levels>200 ng/mL.
참고문헌 (23)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Chen ZH, "Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection : a nationwide study", Hepatol Int, 14, pp.754~764 (2020)
- Pesi B, "Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion : results from a retrospective multicentric study", Am J Surg, 210, pp.35~44 (2015)
- Peng ZW, "Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus", Cancer, 118, pp.4725~4736 (2012)
- Roayaie S, "Resection of hepatocellular carcinoma with macroscopic vascular invasion", Ann Surg Oncol, 20, pp.3754~3760 (2013)
- Kokudo T, "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion", J Hepatol, 65, pp.938~943 (2016)
- Xu X, "Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi", Hepatobiliary Pancreat Dis Int, 3, pp.341~344 (2004)
- Lee KW, "Macrovascular invasion is not an absolute contraindication for living donor liver transplantation", Liver Transpl, 23, pp.19~27 (2017)
- Levi Sandri GB, "Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation", Hepatobiliary Surg Nutr, 6, pp.44~48 (2017)
- 한광협, "Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy", Yonsei Medical Journal, 57(5), pp.1276~1281 (2016), 연세대학교의과대학[DOI]
- Choi HJ, "The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation", Liver Transpl, 23, pp.1023~1031 (2017)
- Shi J, "A new classification for hepatocellular carcinoma with portal vein tumor thrombus", J Hepatobiliary Pancreat Sci, 18, pp.74~80 (2011)
- Zheng N, "Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus", Medicine (Baltimore), 95, pp.e3959~ (2016)
- 이정민, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis", Clinical and Molecular Hepatology, 22(1), pp.160~167 (2016), 대한간학회
- Zhang XP, "Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus : a systematic review and meta-analysis", BMC Cancer, 17, pp.902~ (2017)
- Su F, "Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus", Cancer Med, 7, pp.4387~4395 (2018)
- Yu JI, "Treatment of naïve HCC combined with segmental or subsegmental portal vein tumor thrombosis : liver resection versus TACE followed by radiotherapy", Anticancer Res, 38, pp.4919~4925 (2018)
- Zhang XP, "A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection : a large-scale, multicenter study", Eur J Surg Oncol, 45, pp.1644~1651 (2019)
- Zhang LX, "The prognostic significance of serum gamma-glutamyltransferase levels and AST", ALT in primary hepatic carcinoma, 2019, pp.19, 841~
- Jee SH, "Metabolomics profiles of hepatocellular carcinoma in a Korean prospective cohort: the Korean Cancer Prevention Study-II", Cancer Prev Res (Phila), 11, pp.303~312 (2018)
- Wang ZX, "Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma", Hepatobiliary Pancreat Dis Int, 14, pp.178~185 (2015)
- Austin PC, "Moving towards best practice when using inverse probability of treatment weighting(IPTW)using the propensity score to estimate causal treatment effects in observational studies", Stat Med, 34, pp.3661~3679 (2015)